Synergice

Synergice Therapeutics is a Houston-based biotechnology company focused on developing innovative immuno-oncology therapies to treat "cold" tumors that are resistant to standard immunotherapies. Spun out of the MD Anderson Cancer Center, the company leverages a proprietary platform to identify synergistic therapeutic combinations that remodel the immunosuppressive tumor microenvironment. Their primary focus is on converting non-immunogenic tumors into immunogenic ones by targeting key pathways such as TGF-beta and adenosine. By enhancing immune cell infiltration and activation, Synergice aims to improve outcomes for patients with difficult-to-treat cancers, including prostate and pancreatic malignancies. The company is currently advancing its lead programs through pre-clinical development.